Idiopathic Pulmonary Fibrosis Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Idiopathic Pulmonary Fibrosis Pipeline Analysis report covers 57 drugs currently in different phases of development. Idiopathic Pulmonary Fibrosis is a disease characterised by scarring of pulmonary tissue and thus leading to reduced lung efficiency and difficult breathing. The scarring causes the lungs to become stiffer and lose their elasticity. Symptoms of the disease are breathlessness, persistent cough, clubbing and fatigue. Diagnoses is done by a chest x-ray, breathing tests and bronchoscopy. Treatment include pulmonary rehabilitation, oxygen therapy and medication to help with symptoms and scarring.
The report provides Idiopathic Pulmonary Fibrosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are AdAlta Limited, Asahi Kasei Pharma Corporation, Capstone Therapeutics Corp., Galectin Therapeutics, Kadmon Corporation, LLC, Prometic Life Sciences Inc., Reviva Pharmaceuticals Inc., Synairgen plc and OliX Pharmaceuticals, Inc. among others.
By Molecule Type
By Route of Administration